

# Winterworkshop in Leogang Teil 1

## Geschlechtersensible Medizin: Bedeutung für die Uro-Onkologie

Ute Seeland

### Literatur

1. Dunford A. et al. Tumor-suppressor genes that escape from X-inactivation contribute to cancer sex bias. *Nat Genet* 2017; 49: 10–16
2. RKI. Zentrum für Krebsregisterdaten (ZfKD). Stand 29.11.2021. ([https://www.rki.de/DE/Content/Gesundheitsmonitoring/Krebsregisterdaten/krebs\\_no\\_de.html](https://www.rki.de/DE/Content/Gesundheitsmonitoring/Krebsregisterdaten/krebs_no_de.html))
3. Niedermaier T et al. To what extent is male excess risk of advanced colorectal neoplasms explained by known risk factors? Results from a large German screening population. *Int J Cancer* 2021; 149(11): 1877–86
4. Reza SA et al. *Frontiers in Oncology* 2020
5. <https://hdr.undp.org/data-center/thematic-composite-indices/gender-inequality-index#/indicies/GII>
6. Henning A et al. Do differences in clinical symptoms and referral patterns contribute to the gender gap in bladder cancer? *BJU Int* 2013; 112(1): 68–73
7. Burge F & Kockelbergh R. Closing the Gender Gap: Can We Improve Bladder Cancer Survival in Women? – A Systematic Review of Diagnosis, Treatment and Outcomes. *Urol Int* 2016; 97: 373–9
8. Gakis G & Weckermann D. Geschlechtsassoziierte Unterschiede beim Harnblasenkarzinom. *Die Urologie* 2022; 61: 1060–7
9. Lucca I et al. Sex steroids and gender differences in non-muscle invasive bladder cancer. *Curr Opin Urol* 2014; 24(5): 500–5
10. Dobruch J et al. Gender and bladder cancer: a collaborative review of etiology, biology, and outcomes. *Eur Urol* 2016; 69(2): 300–10